全文获取类型
收费全文 | 11526篇 |
免费 | 855篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 441篇 |
妇产科学 | 259篇 |
基础医学 | 1554篇 |
口腔科学 | 91篇 |
临床医学 | 1953篇 |
内科学 | 2072篇 |
皮肤病学 | 75篇 |
神经病学 | 1158篇 |
特种医学 | 193篇 |
外科学 | 919篇 |
综合类 | 153篇 |
一般理论 | 29篇 |
预防医学 | 1401篇 |
眼科学 | 223篇 |
药学 | 826篇 |
中国医学 | 22篇 |
肿瘤学 | 981篇 |
出版年
2023年 | 106篇 |
2022年 | 65篇 |
2021年 | 203篇 |
2020年 | 216篇 |
2019年 | 289篇 |
2018年 | 298篇 |
2017年 | 244篇 |
2016年 | 275篇 |
2015年 | 270篇 |
2014年 | 361篇 |
2013年 | 572篇 |
2012年 | 875篇 |
2011年 | 891篇 |
2010年 | 474篇 |
2009年 | 435篇 |
2008年 | 779篇 |
2007年 | 814篇 |
2006年 | 788篇 |
2005年 | 723篇 |
2004年 | 678篇 |
2003年 | 626篇 |
2002年 | 600篇 |
2001年 | 126篇 |
2000年 | 103篇 |
1999年 | 133篇 |
1998年 | 112篇 |
1997年 | 93篇 |
1996年 | 86篇 |
1995年 | 98篇 |
1994年 | 76篇 |
1993年 | 72篇 |
1992年 | 77篇 |
1991年 | 74篇 |
1990年 | 64篇 |
1989年 | 58篇 |
1988年 | 65篇 |
1987年 | 59篇 |
1986年 | 53篇 |
1985年 | 58篇 |
1984年 | 58篇 |
1983年 | 41篇 |
1982年 | 35篇 |
1981年 | 35篇 |
1980年 | 39篇 |
1979年 | 32篇 |
1978年 | 30篇 |
1977年 | 18篇 |
1976年 | 21篇 |
1975年 | 19篇 |
1974年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Cynthia S. E. Hendrikse MD Phyllis van der Ploeg MD PhD Nienke M. A. van de Kruis MD Jody H. C. Wilting MD Floor Oosterkamp BSc Pauline M. M. Theelen MSc Christianne A. R. Lok MD PhD Joanne A. de Hullu MD PhD Huberdina P. M. Smedts MD PhD M. Caroline Vos MD PhD Brenda M. Pijlman MD Loes F. S. Kooreman MD Johan Bulten MD PhD Marjolein H. F. M. Lentjes-Beer MD PhD Steven L. Bosch MD PhD Anja van de Stolpe MD PhD Sandrina Lambrechts MD PhD Ruud L. M. Bekkers MD PhD Jurgen M. J. Piek MD PhD 《Cancer》2023,129(9):1361-1371
Background
Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.Results
Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS. 相似文献2.
Stephanie H. Ameis John D. Haltigan Rachael E. Lyon Amanda Sawyer Pat Mirenda Connor M. Kerns Isabel M. Smith Tracy Vaillancourt Joanne Volden Charlotte Waddell Lonnie Zwaigenbaum Teresa Bennett Eric Duku Mayada Elsabbagh Stelios Georgiades Wendy J. Ungar Anat Zaidman-Zait Meng-Chuan Lai Peter Szatmari for the Pathways in ASD Study Team 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(5):553-562
3.
4.
5.
Pharmaceutical Research - Transporters at the blood-cerebrospinal fluid (CSF) barrier (BCSFB) play active roles in removing drugs and toxins from the CSF. The goal of this study is to develop a... 相似文献
6.
7.
Adrian Farrugia Suzanne Fraser Robyn Dwyer Renae Fomiatti Joanne Neale Paul Dietze John Strang 《Sociology of health & illness》2019,41(2):427-443
‘Take‐home naloxone’ refers to a life‐saving intervention in which a drug (naloxone) is made available to nonmedically trained people for administration to other people experiencing an opioid overdose. In Australia, it has not been taken up as widely as would be expected, given its life‐saving potential. We consider the actions of take‐home naloxone, focusing on how care relations shape its uses and effects. Mobilising Science and Technology Studies insights, we suggest that the uses and effects of naloxone are co‐produced within social relations and, therefore, this initiative ‘affords’ multiple outcomes. We argue that these affordances are shaped by a politics of care, and that these politics relate to uptake. We analyse two complementary case studies, drawn from an interview‐based project, in which opioid consumers discussed take‐home naloxone and its uses. Our analysis maps the ways take‐home naloxone can afford (i) a regime of care within an intimate partnership (allowing a terminally ill man to more safely consume opioids) and (ii) a political process of care (in which a consumer takes care of others treated with the medication by administering it ‘gently’). We conclude by exploring the political affordances of a politics of care approach for the uptake of take‐home naloxone. 相似文献
8.
Mohamed E. Salem J. Nicholas Bodor Alberto Puccini Joanne Xiu Richard M. Goldberg Axel Grothey W. Michael Korn Anthony F. Shields William M Worrilow Edward S. Kim Heinz-Josef Lenz John L. Marshall Michael J. Hall 《International journal of cancer. Journal international du cancer》2020,147(10):2948-2956
Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in a diverse sample of tumors. Hypothesized differences were identified by the protein/gene affected/mutated and the tumor histology/primary site. Overall, 1057 MSI-H tumors were identified from the 32 932 tested. MSI was examined by NGS using 7000+ target microsatellite loci. TMB was calculated using only nonsynonymous missense mutations sequenced with a 592-gene panel; a subset of MSI-H tumors also had MMR IHC performed. Analyses examined TMB by MMR protein heterodimer impacted (loss of MLH1/PMS2 vs. MSH2/MSH6 expression) and gene-specific mutations. The sample was 54.6% female; mean age was 63.5 years. Among IHC tested tumors, loss of co-expression of MLH1/PMS2 was more common (n = 544/705, 77.2%) than loss of MSH2/MSH6 (n = 81/705, 11.5%; P < .0001), and was associated with lower mean TMB (MLH1/PMS2: 25.03 mut/Mb vs MSH2/MSH6 46.83 mut/Mb; P < .0001). TMB also varied by tumor histology: colorectal cancers demonstrating MLH1/PMS2 loss had higher TMBs (33.14 mut/Mb) than endometrial cancers (20.60 mut/Mb) and other tumors (25.59 mut/Mb; P < .0001). MMR gene mutations were detected in 42.0% of tumors; among these, MSH6 mutations were most common (25.7%). MSH6 mutation patterns showed variability by tumor histology and TMB. TMB varies by underlying cause(s) of MSI and tumor histology; this heterogeneity may contribute to differences in response to ICI. 相似文献
9.
10.
Joanne E. Mortimer Laura Kruper Jae Jung Louise Wong Jill Cooper Daphne Stewart Samuel Chung Kim Wai Yu Sanjeet Dadwal Yuan Yuan 《Cancer chemotherapy and pharmacology》2020,85(3):501-507
We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem.
Treating physicians and advanced practice partners identified women who developed infections while on treatment with pertuzumab and trastuzumab alone or in combination with chemotherapy and enrolled them onto this registry trial. Between March, 2014 and May, 2017, 48 patients with HER2-positive breast cancers were reported to have 59 individual infections. The median age was 48 years. Twenty-four patients received neoadjuvant therapy, 17 were treated for metastatic disease, and 7 were treated in the adjuvant setting. Pertuzumab and trastuzumab were combined with carboplatin and docetaxel in 24 (49%) patients, docetaxel in 10 (21%), nab-paclitaxel in 12 (24%), and without other agents in 2 (4%). Granulocyte growth factors were administered in 24 (49%) patients and no patients were documented to be neutropenic. Folliculitis developed in 25 (52%) patients and was counted as a single infection. Abscesses developed at a number of sites in 24 (49%) patients, including a septic knee requiring total knee replacement. Paronychia occurred in 7 (15%) patients, and 5 (10%) developed cellulitis. When cultures were obtained, Gram-positive cocci were consistently identified. Hypogammaglobulinemia was documented in 14 (36%) of the 33 patients tested. Our data continue to support an increased risk of infections with Gram-positive cocci as a potentially serious adverse event in women treated with pertuzumab and trastuzumab. 相似文献